I-Mab: Fast-Growing Biopharma Company Led by Experienced Team
I-Mab's founder previously served in top management positions at the China center of GlaxoSmithKline, a British multinational pharma developer.
I-Mab Biopharma Co., a Chinese clinical-stage biopharmaceutical company, has filed for an initial public offering with the U.S. Securities and Exchange Commission in late October, targeting to raise up to $100 million.
Led by an experienced management team, I-Mab is exclusively focused on developing innovative biologics of first-in-class or best-in-class potential in the therapeutic areas of immuno-oncology and autoimmune diseases on a global scope.
Founded in 2014, I-Mab aims to establish a "Fast-to-Market" China pipeline and a "Fast-to-PoC" (proof of concept) global pipeline. According to the company's filing, I-Mab has obtained IND approvals from the NMPA for five of its drug candidates, TJ202, TJ301, TJ107, TJC4 and TJD5. In addition, the company has obtained IND approvals from the FDA for three of its drug candidates, TJC4, TJD5 and TJM2, which are undergoing phase 1 trials in the United States.
A number of the company's leaders have strong academic background and senior management experience in medical and biological fields and other biopharmaceutical companies.
I-Mab's founder and honorary chairman, Dr. Jingwu Zhang Zang, previously served as the chief scientific officer and president of Simcere Pharmaceutical Group and BioSciKin Co. Ltd. Prior to that, Dr. Zang held senior management positions at GlaxoSmithKline (GSK), as the global senior vice president and head of GSK's research and development in China for six years. Dr. Zang received his M.D and Ph.D. in neuroimmunology from Shanghai Second Medical University (now part of Shanghai Jiaotong University) and University of Brussels and obtained his U.S. medical license from the Texas Medical Board through a clinical residency at Baylor College of Medicine in Houston.
Dr. Joan Huaqiong Shen, with more than 15 years of experience in the biopharmaceutical industry, currently serves as I-Mab's chief executive officer. Prior to joining I-Mab, she served as the vice president and development head of Janssen Pharmaceutical Companies of Johnson & Johnson. Dr. Shen received her M.D. and Ph.D. in anatomy/neuroscience from Southeast University Medical College and Indiana University School of Medicine.
The director and president, Dr. Zheru Zhang, served in lead positions in several biotech companies since 2006. He served as president at Tasgen Biotech (Tianjin) Co. Ltd. and the chief executive officer at Shanghai JMT-Bio Co. Dr. Zhang received his Ph.D. in chemistry from the University of Alberta in Canada.
I-Mab expects to trade its shares on the Nasdaq Global Market under the symbol "IMAB." The exact amount of the offering and the pricing of shares have yet to be determined.